(Q38082420)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23417505%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23417505%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23417505%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Norman Stockbridge

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23417505%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Joel Morganroth

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23417505%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Rashmi R Shah

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23417505%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

1 reference

1 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23417505%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23417505%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23417505%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23417505%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

167-182

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23417505%20AND%20SRC:MED&resulttype=core&format=json

Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Current status of class III antiarrhythmic drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Is QT interval prolongation harmful? A regulatory perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Drug induced QT prolongation and torsades de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Can pharmacogenetics help rescue drugs withdrawn from the market?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Development of drugs that alter ventricular repolarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Testing for positive control activity in a thorough QTc study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Statistical characteristics of moxifloxacin-induced QTc effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Creation of a Knowledge Management System for QT Analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Assessing electrocardiographic data quality and possible replacement of pharmacologic positive control in thorough QT/QTc studies by investigations of drug-free QTc stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Experimental models of torsades de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

A family of potassium channel genes related to eag in Drosophila and mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Exploring the hidden danger of noncardiac drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Evaluation of vardenafil and sildenafil on cardiac repolarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Clinical assessment of drug-induced QT prolongation in association with heart rate changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Assessing proarrhythmic potential of drugs when optimal studies are infeasible.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

The Cardiac Safety Research Consortium electrocardiogram warehouse: thorough QT database specifications and principles of use for algorithm development and testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Electrocardiographic assessment for therapeutic proteins—scientific discussion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Drug-induced torsades de pointes and implications for drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Amplification of spatial dispersion of repolarization underlies sudden cardiac death associated with catecholaminergic polymorphic VT, long QT, short QT and Brugada syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Practitioner acceptance of the dofetilide risk-management program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Evaluation of the dofetilide risk-management program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

PharmGKB very important pharmacogene: SLCO1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

QT PRODACT: a multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Drug‐induced QT interval prolongation: regulatory perspectives and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0016-Z

Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death

21 January 2018

1 reference

12 December 2020

Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability

1 reference

12 December 2020

Cellular and Ionic Mechanisms Underlying Erythromycin-Induced Long QT Intervals and Torsade de Pointes

1 reference

12 December 2020

The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France

1 reference

12 December 2020

Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic

1 reference

12 December 2020

Cardiac Arrest Associated With Combination Cisapride and Itraconazole Therapy

1 reference

12 December 2020

KCNH2 pharmacogenomics summary

1 reference

12 December 2020

Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics

1 reference

12 December 2020

A viewpoint on drugs that prolong the QTc interval

1 reference

12 December 2020

Lessons from cisapride

1 reference

12 December 2020

Significance of QT prolongation in the electrocardiogram: based on the study of 168 cases

1 reference

12 December 2020

Population Pharmacokinetic and Concentration-QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies

1 reference

12 December 2020

QTc Interval Prolongation: Is It Beneficial or Harmful? Symposium proceedings. Philadelphia, Pennsylvania, October 29, 1992

1 reference

12 December 2020